Despite Big Move, Aerie Pharma (AERI) Not Getting Credit for Drug Potential - Brean Capital

September 15, 2016 9:33 AM EDT
Get Alerts AERI Hot Sheet
Price: $42.50 +2.16%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AERI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Brean Capital analyst Difei Yang reiterated a Buy rating and $48 price target on Aerie Pharma (NASDAQ: AERI) after announced top-line efficacy results from its Phase III “Mercury 1” clinical trial for Roclatan, a fixed dose combination product designed to treat glaucoma.

Yang said the results, reconfirming potential for Roclatan, showed statistically significant superiority over both latanoprost and Rhopressa at each of the nine measured time points with baseline IOPs from above 20 to below 36 mmHg.

"While the share price went up to ~$34/share during after-market session, we believe it is still not giving the full credit of potential commercial value of Rhopressa and Roclatan," the analyst aid.

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $21.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Brean Capital

Add Your Comment